Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment | MicrobiomeTrials← Back to trialsNCT06199232
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
CompletedNAINTERVENTIONAL
Trial Details
Start: 2024-01-23Est. Completion: 2026-07-10
Enrollment target: 47 participants Locations- Peking Univerisity Cancer Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Colorectal NeoplasmsNeoplasmsIntrahepatic CholangiocarcinomaAdrenocortical CarcinomaMetastasis, Neoplasm
Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …
Bethesda, United StatesEst. completion Dec 31, 2029
CRC (Colorectal Cancer)
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiothe…
Wuhan, China
Est. completion Jun 30, 2029